查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1400507

全球细胞/基因疗法 CDMO 市场（2024 年版）：按类型、应用、适应症、地区和国家、市场考察和预测进行分析（2024-2029 年）

Global Cell and Gene Therapy CDMO Market (2024 Edition): Analysis By Type (Cell Therapy, Gene Therapy, Gene-modified Cell Therapies), Application (Clinical, Pre-clinical), Indication, By Region, By Country: Market Insights and Forecast (2024-2029)
出版日期: | 出版商: Azoth Analytics | 英文 260 Pages | 订单完成后即时交付

价格

全球细胞和基因治疗 CDMO 市场规模预计将从 2022 年的 25.4 亿美元成长，2024-2029 年预测期间复合年增长率为 30.75%。在细胞和基因疗法不断进步的推动下，市场呈现健康成长和不断增长的需求。由于治疗范围的扩大和有利的法规环境，该市场预计将继续扩大，因为它在各种疾病的创新治疗方法的开发和商业化中发挥关键作用。在行业参与者大量投资的推动下，市场预计将出现巨大增长。

全球细胞和基因治疗产品线正在不断扩大，涵盖癌症、罕见疾病和遗传性疾病等广泛的治疗领域。随着越来越多的治疗方法通过临床试验并走向商业化，对製造、製程开发和扩大规模的 CDMO 服务的需求不断增加。

全球细胞和基因疗法 CDMO 组织正在扩大，这是推动细胞和基因疗法在全球范围内全面扩张的主要因素之一。随着全球对先进细胞和基因疗法的需求增加，CDMO 正在各地积极建立生产设施，以满足生物技术和製药公司不断变化的需求。如今，CDMO已成为药品生产不可或缺的一部分。在过去的十年中，由于併购环境更加活跃，CDMO 的影响力增加。目前有超过 600 个活跃的受託製造厂商(CDMO) 为本地和国际市场提供服务。 CDMO 提供特定的专业知识，帮助「大型製药企业」和小型发明家将其产品快速推向市场。

生技药品的崛起可以从对新生技药品生产设施进行大量投资的 CDMO 数量看出。这些公司包括勃林格殷格翰（投资8.27亿美元）、三星生物製品（投资17亿美元）、Lonza（投资9.35亿美元）、Fujifilm Diosynth Biotechnologies（投资20亿美元）等。

此外，在全球范围内扩张使 CDMO 能够满足当地的监管需求，提供客製化的製造解决方案，并增加需要其服务的客户的可及性。 CDMO 在全球主要市场的存在使他们能够提供更具适应性和敏捷性的解决方案。这将加速基因和细胞疗法的开发和全球商业化。

限制市场成长的突出因素之一是病毒载体的高製造成本。病毒载体作为将治疗基因传递至目标细胞的载体，对于基因和细胞疗法的发展至关重要。病毒载体的生产是一个复杂的过程，通常需要专门的技术、严格的品管标准和专门的设备。

目前有五种类型的病毒载体用于基因治疗。 AAV 的市场占有率最高，其次是慢病毒、腺病毒、单纯疱疹病毒和逆转录病毒。根据 Roland Berger Insights 的数据，单给药载体的製造成本可能为 100 万美元至 200 万美元，预计每批次为 300 万美元至 700 万美元。因此，病毒载体的高製造成本阻碍了细胞和基因疗法的广泛商业化和可用性。

该报告审视了全球细胞和基因治疗 CDMO 市场，并提供了包括市场规模和预测、区域和細項分析以及主要趋势和机会在内的资讯。

目录

第一章 市集背景

  • 产品范围和产品前景
  • 执行摘要
  • 调查方法

第二章 战略建议

第三章全球细胞/基因治疗CDMO市场：实绩与预测（2019-2029）

  • 宏观经济因素对细胞和基因治疗CDMO市场的影响分析
  • 细胞/基因治疗管线
  • 临床AAV基因治疗
  • 核准/药物：按治疗领域
  • 核准的治疗方法，管道
  • 基因治疗管线
  • 基因治疗的分解
  • 基因治疗管道：最常见的目标治疗领域
  • 细胞/基因治疗的形势
  • 全球细胞和基因疗法 CDMO 市场：仪表板
  • 全球细胞和基因治疗 CDMO 市场：市场金额评估（2019-2029）
  • 全球细胞和基因治疗 CDMO 市场：最新发展和核准的细胞和基因治疗
  • 全球细胞和基因疗法 CDMO 市场：近期併购和发展
  • COVID-19 对细胞和基因治疗 CDMO 市场的影响
  • 按类型分類的全球细胞和基因治疗 CDMO市场区隔
    • 全球细胞和基因疗法 CDMO 市场：按类型、概述
    • 全球细胞/基因治疗CDMO市场规模：细胞治疗（金额）（2019-2029）
    • 全球细胞/基因治疗CDMO市场规模：基因治疗（金额）（2019-2029）
    • 全球细胞/基因治疗CDMO市场规模：基因改造细胞治疗（金额）（2019-2029）
  • 全球细胞和基因治疗 CDMO市场区隔：按应用
    • 全球细胞/基因疗法 CDMO 市场：按应用、概述
    • 全球细胞/基因治疗 CDMO 市场规模：临床（金额）（2019-2029）
    • 全球细胞与基因治疗 CDMO 市场规模：临床前（金额）（2019-2029）
  • 全球细胞和基因治疗 CDMO市场区隔：按适应症
    • 全球细胞和基因疗法 CDMO 市场：按适应症概述
    • 全球细胞和基因治疗 CDMO 市场规模：肿瘤疾病（金额）（2019-2029）
    • 全球细胞/基因治疗 CDMO 市场规模：感染疾病（金额）（2019-2029）
    • 全球细胞和基因治疗 CDMO 市场规模：神经系统疾病（金额）（2019-2029）
    • 全球细胞/基因治疗 CDMO 市场规模：其他适应症（金额）（2019-2029）

第四章全球细胞与基因治疗 CDMO 市场：区域分析

  • 研究区域范围
  • 区域简介

第五章美洲细胞与基因治疗 CDMO 市场：实绩与预测（2019-2029）

  • 美洲细胞与基因治疗 CDMO 市场：简介
  • 美洲细胞与基因治疗 CDMO 市场：市场金额评估（2019-2029）
  • 美洲细胞与基因疗法 CDMO 市场：关键驱动因素
  • 美洲细胞与基因治疗 CDMO 市场：細項分析
  • 按类型分類的美洲细胞和基因治疗 CDMO市场区隔
  • 美洲细胞和基因治疗 CDMO市场区隔
  • 美洲细胞和基因治疗 CDMO市场区隔按适应症细分
  • 按国家/地区分類的美洲细胞和基因治疗 CDMO市场区隔
    • 美洲细胞和基因疗法 CDMO 市场：按国家/地区、概述
    • 美国细胞/基因治疗 CDMO 市场：市场规模和复合年增长率（2019-2029）
    • 加拿大细胞和基因治疗 CDMO 市场：市场规模和复合年增长率（2019-2029）
    • 其他美洲细胞和基因治疗 CDMO 市场：市场规模和复合年增长率（2019-2029）

第六章欧洲细胞与基因治疗 CDMO 市场：实绩与预测（2019-2029）

  • 欧洲细胞和基因治疗 CDMO 市场：简介
  • 欧洲细胞与基因治疗 CDMO 市场：市场金额评估（2019-2029）
  • 欧洲细胞与基因疗法 CDMO 市场：关键驱动因素
  • 欧洲细胞与基因治疗 CDMO 市场：細項分析
  • 欧洲细胞和基因治疗 CDMO市场区隔按类型细分
  • 欧洲细胞和基因治疗 CDMO市场区隔：按应用
  • 欧洲细胞和基因治疗 CDMO市场区隔：按适应症
  • 按国家/地区分類的欧洲细胞和基因治疗 CDMO市场区隔
    • 欧洲细胞和基因治疗 CDMO 市场：按国家/地区划分，概述
    • 英国细胞和基因治疗 CDMO 市场：市场规模和复合年增长率（2019-2029）
    • 德国细胞和基因治疗CDMO市场：市场规模和复合年增长率（2019-2029）
    • 法国细胞和基因治疗 CDMO 市场：市场规模和复合年增长率（2019-2029）
    • 义大利细胞和基因治疗CDMO市场：市场规模和复合年增长率（2019-2029）
    • 其他欧洲细胞和基因治疗 CDMO 市场：市场规模和复合年增长率（2019-2029）

第七章亚太细胞与基因治疗 CDMO 市场：实绩与预测（2019-2029）

  • 亚太细胞与基因治疗 CDMO 市场：简介
  • 亚太细胞与基因治疗 CDMO 市场：市场金额评估（2019-2029）
  • 亚太细胞与基因疗法 CDMO 市场：关键驱动因素
  • 亚太细胞与基因治疗 CDMO 市场：細項分析
  • 亚太地区细胞和基因治疗 CDMO市场区隔按类型细分
  • 亚太地区细胞和基因治疗 CDMO市场区隔
  • 亚太地区细胞和基因治疗 CDMO市场区隔
  • 按国家/地区分類的亚太地区细胞和基因治疗 CDMO市场区隔
    • 亚太细胞和基因治疗 CDMO 市场：按国家/地区划分，概述
    • 中国细胞与基因治疗CDMO市场：市场规模及复合年增长率（2019-2029）
    • 日本细胞/基因治疗CDMO市场：市场规模与复合年增长率（2019-2029）
    • 韩国细胞和基因治疗CDMO市场：市场规模和复合年增长率（2019-2029）
    • 印度细胞和基因治疗 CDMO 市场：市场规模和复合年增长率（2019-2029）
    • 其他亚太细胞和基因治疗 CDMO 市场：市场规模和复合年增长率（2019-2029）

第8章中东和非洲细胞和基因治疗CDMO市场：实绩和预测（2019-2029）

  • 中东和非洲细胞和基因治疗 CDMO 市场：简介
  • 中东和非洲细胞和基因治疗 CDMO 市场：市场金额评估（2019-2029）
  • 中东和非洲细胞和基因治疗 CDMO 市场：关键驱动因素
  • 中东和非洲细胞和基因治疗 CDMO 市场：細項分析
  • 中东和非洲细胞和基因治疗 CDMO市场区隔按类型细分
  • 中东和非洲细胞和基因治疗 CDMO市场区隔
  • 中东和非洲细胞和基因治疗 CDMO市场区隔

第九章市场动态

  • 评估市场动态对全球细胞和基因治疗 CDMO 市场的影响
  • 促进因素
  • 抑制因素
  • 趋势

第10章产业生态系分析

  • 价值链分析
  • 波特五力分析模型

第十一章竞争定位

  • 企业产品定位
  • Oxford Biomedica病毒载体产品的竞争定位
  • 市场地位矩阵
  • 细胞和基因治疗CDMO市场市场占有率分析
  • 公司简介
    • Oxford Biomedica
    • Lonza Group AG
    • Catalent, Inc.
    • Samsung Biologics
    • WuXi Biologics
    • Pfizer CentreOne
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories International, Inc.
    • Novartis AG

Executive Summary

Azoth Analytics has released a research report titled "Global Cell and Gene Therapy CDMO Market (2024 Edition)" which provides a complete analysis of the Global Cell and Gene Therapy CDMO Market industry in terms of market segmentation by Type (Cell Therapy, Gene Therapy, Gene-modified Cell Therapies), Application (Clinical, Pre-clinical), Indication (Oncology Diseases, Infectious Diseases, Neurological Disorder, Others) for the historical period of 2019-2022, estimates of 2023 and the forecast for 2024-2029.

The Global Cell and Gene Therapy CDMO market valued at USD 2.54 billion in 2022 is expected to grow at a CAGR of 30.75% during the forecast period of 2024-2029. The global Cell and Gene Therapy CDMO market has been experiencing robust growth and escalating demand, propelled by continuous advancements in cell and gene therapies. With a broadening scope of therapeutic areas and a favourable regulatory environment, the global Cell and Gene Therapy CDMO market is poised for sustained expansion as it plays a pivotal role in the development and commercialization of ground-breaking therapies for various diseases. The global Cell and Gene Therapy CDMO market is expected to grow at an extraordinary rate driven by significant investments from industry players.

The global pipeline of cell and gene therapies has been expanding, covering a wide range of therapeutic areas, including oncology, rare diseases, and genetic disorders. As more therapies advance through clinical trials and toward commercialization, the demand for CDMO services for manufacturing, process development, and scale-up increases.

Global CDMO organisations for cell and gene therapy are expanding, and this is one of the main factors propelling the global Cell and Gene Therapy's overall expansion. With the increasing global demand for advanced cell and gene therapies, CDMOs are proactively setting up production facilities in various locations to meet the changing demands of biotechnology and pharmaceutical companies. These days, CDMOs are essential to the manufacturing of pharmaceuticals. Over the past ten years, CDMOs have grown in prominence due to a more dynamic mergers and acquisition landscape. Serving both local and international markets, there are currently over 600 active Contract Development and Manufacturing Organizations (CDMOs). CDMOs provide specific expertise that helps both "Big Pharma" and smaller inventors to launch products sooner.

The rise of biologics is seen by the number of CDMOs making significant investments in brand-new biomanufacturing facilities. These companies include Boehringer Ingelheim (USD827M investment), Samsung Biologics (USD1.7B investment), Lonza (USD935M expansion), and Fujifilm Diosynth Biotechnologies (USD2B investment).

Additionally, by expanding globally, CDMOs can meet regional regulatory needs, provide customised manufacturing solutions, and improve accessibility for customers who need their services. CDMOs can provide more adaptable and responsive solutions by being present in important worldwide markets. This helps to speed up the development and global commercialization of gene and cell therapies.

One prominent factor restraining the growth of the global Cell and Gene Therapy CDMO market is the high cost of producing viral vectors. As carriers of therapeutic genes into target cells, viral vectors are essential to the development of gene and cell therapies. Viral vector production is a complex procedure that frequently involves specialized techniques, stringent quality control standards, and specialized facilities.

There are now five viral vectors in use for gene therapy. AAV have the biggest market share, followed by lentiviruses, adenoviruses, herpes simplex viruses and retroviruses. The vector manufacturing cost for a single dose might be as high as USD 1-2 million, given the expected price of USD 3-7 million per batch, according to Roland Berger Insights. Therefore, the high cost of producing viral vectors hampers cell and gene therapies from being widely commercialised and made accessible, which limits their uptake and hinders the expansion of the Cell and Gene CDMO market.

Scope of the Report

  • The report analyses the Global Cell and Gene Therapy CDMO Market by Value (USD Million).
  • The report presents the analysis of Global Cell and Gene Therapy CDMO Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
  • The report analyses the Global Cell and Gene Therapy CDMO Market by Type (Cell Therapy, Gene Therapy, Gene-modified Cell Therapies).
  • The report analyses the Cell and Gene Therapy CDMO Market by Application (Clinical, Pre-clinical).
  • The report analyses the Cell and Gene Therapy CDMO Market by Indication (Oncology Diseases, Infectious Diseases, Neurological Disorder, Other Indications).
  • The report analyses the Cell and Gene Therapy CDMO Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa).
  • The report analyses the Cell and Gene Therapy CDMO Market by Country (United States, Canada, United Kingdom, Germany, France, Italy, China, Japan, South Korea, India).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Oxford Biomedica, Lonza Group AG, Catalent, Inc., Samsung Biologics, WuXi Biologics, Pfizer CentreOne, Danaher Corporation, Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., Novartis AG.

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

3. Global Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 3.1 Impact Analysis of Macro Economic Factors on Cell and Gene Therapy CDMO Market
  • 3.2 Cell and Gene Therapy Pipeline
  • 3.3 Clinical AAV Gene Therapies
  • 3.4 Approvals & Drugs by Therapy Area
  • 3.5 Approved Therapies and Pipeline
  • 3.6 Gene Therapy Pipeline
  • 3.7 Gene Therapy Breakdown
  • 3.8 Gene Therapy Pipeline: Most Commonly Targeted Therapeutic Areas
  • 3.9 Cell and Gene Therapy Landscape
  • 3.10 Global Cell and Gene Therapy CDMO Market: Dashboard
  • 3.11 Global Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million)
  • 3.12 Global Cell and Gene Therapy CDMO Market: Recent Development & Approved Cell and Gene Therapies
  • 3.13 Global Cell and Gene Therapy CDMO Market: Recent M&A and Developments
  • 3.14 Impact of COVID-19 on Cell and Gene Therapy CDMO Market
  • 3.15 Global Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 3.15.1 Global Cell and Gene Therapy CDMO Market, By Type Overview
    • 3.15.2 Global Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.15.3 Global Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.15.4 Global Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.16 Global Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 3.16.1 Global Cell and Gene Therapy CDMO Market, By Application Overview
    • 3.16.2 Global Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.16.3 Global Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.17 Global Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 3.17.1 Global Cell and Gene Therapy CDMO Market, By Indication Overview
    • 3.17.2 Global Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.17.3 Global Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.17.4 Global Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.17.5 Global Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)

4. Global Cell and Gene Therapy CDMO Market: Regional Analysis

  • 4.1 Regional Coverage of the Study
  • 4.2 Regional Snapshot

5. Americas Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 5.1 Americas Cell and Gene Therapy CDMO Market: Snapshot
  • 5.2 Americas Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
  • 5.3 Americas Cell and Gene Therapy CDMO Market: Key Factors
  • 5.4 Americas Cell and Gene Therapy CDMO Market: Segment Analysis
  • 5.5 Americas Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 5.5.1 Americas Cell and Gene Therapy CDMO Market, By Type Overview
    • 5.5.2 Americas Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.5.3 Americas Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.5.4 Americas Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.6 Americas Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 5.6.1 Americas Cell and Gene Therapy CDMO Market, By Application Overview
    • 5.6.2 Americas Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.6.3 Americas Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.7 Americas Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 5.7.1 Americas Cell and Gene Therapy CDMO Market, By Indication Overview
    • 5.7.2 Americas Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.7.3 Americas Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.7.4 Americas Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.7.5 Americas Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.8 Americas Cell and Gene Therapy CDMO Market Segmentation: By Country
    • 5.8.1 Americas Cell and Gene Therapy CDMO Market, By Country Overview
    • 5.8.2 United States Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 5.8.2.1 United States Cell and Gene Therapy CDMO Market, By Type
      • 5.8.2.2 United States Cell and Gene Therapy CDMO Market, By Application
      • 5.8.2.3 United States Cell and Gene Therapy CDMO Market, By Indication
    • 5.8.3 Canada Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 5.8.3.1 Canada Cell and Gene Therapy CDMO Market, By Type
      • 5.8.3.2 Canada Cell and Gene Therapy CDMO Market, By Application
      • 5.8.3.3 Canada Cell and Gene Therapy CDMO Market, By Indication
    • 5.8.4 Rest of Americas Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 5.8.4.1 Rest of Americas Cell and Gene Therapy CDMO Market, By Type
      • 5.8.4.2 Rest of Americas Cell and Gene Therapy CDMO Market, By Application
      • 5.8.4.3 Rest of Americas Cell and Gene Therapy CDMO Market, By Indication

6. Europe Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 6.1 Europe Cell and Gene Therapy CDMO Market: Snapshot
  • 6.2 Europe Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
  • 6.3 Europe Cell and Gene Therapy CDMO Market: Key Factors
  • 6.4 Europe Cell and Gene Therapy CDMO Market: Segment Analysis
  • 6.5 Europe Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 6.5.1 Europe Cell and Gene Therapy CDMO Market, By Type Overview
    • 6.5.2 Europe Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.5.3 Europe Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.5.4 Europe Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.6 Europe Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 6.6.1 Europe Cell and Gene Therapy CDMO Market, By Application Overview
    • 6.6.2 Europe Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.6.3 Europe Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.7 Europe Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 6.7.1 Europe Cell and Gene Therapy CDMO Market, By Indication Overview
    • 6.7.2 Europe Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.7.3 Europe Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.7.4 Europe Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.7.5 Europe Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.8 Europe Cell and Gene Therapy CDMO Market Segmentation: By Country
    • 6.8.1 Europe Cell and Gene Therapy CDMO Market, By Country Overview
    • 6.8.2 United Kingdom Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.2.1 United Kingdom Cell and Gene Therapy CDMO Market, By Type
      • 6.8.2.2 United Kingdom Cell and Gene Therapy CDMO Market, By Application
      • 6.8.2.3 United Kingdom Cell and Gene Therapy CDMO Market, By Indication
    • 6.8.3 Germany Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.3.1 Germany Cell and Gene Therapy CDMO Market, By Type
      • 6.8.3.2 Germany Cell and Gene Therapy CDMO Market, By Application
      • 6.8.3.3 Germany Cell and Gene Therapy CDMO Market, By Indication
    • 6.8.4 France Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.4.1 France Cell and Gene Therapy CDMO Market, By Type
      • 6.8.4.2 France Cell and Gene Therapy CDMO Market, By Application
      • 6.8.4.3 France Cell and Gene Therapy CDMO Market, By Indication
    • 6.8.5 Italy Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.5.1 Italy Cell and Gene Therapy CDMO Market, By Type
      • 6.8.5.2 Italy Cell and Gene Therapy CDMO Market, By Application
      • 6.8.5.3 Italy Cell and Gene Therapy CDMO Market, By Indication
    • 6.8.6 Rest of Europe Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.6.1 Rest of Europe Cell and Gene Therapy CDMO Market, By Type
      • 6.8.6.2 Rest of Europe Cell and Gene Therapy CDMO Market, By Application
      • 6.8.6.3 Rest of Europe Cell and Gene Therapy CDMO Market, By Indication

7. Asia Pacific Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 7.1 Asia Pacific Cell and Gene Therapy CDMO Market: Snapshot
  • 7.2 Asia Pacific Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
  • 7.3 Asia Pacific Cell and Gene Therapy CDMO Market: Key Factors
  • 7.4 Asia Pacific Cell and Gene Therapy CDMO Market: Segment Analysis
  • 7.5 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 7.5.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Type Overview
    • 7.5.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.5.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.5.4 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.6 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 7.6.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Application Overview
    • 7.6.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.6.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.7 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 7.7.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Indication Overview
    • 7.7.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.7.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.7.4 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.7.5 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.8 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Country
    • 7.8.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Country Overview
    • 7.8.2 China Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.2.1 China Cell and Gene Therapy CDMO Market, By Type
      • 7.8.2.2 China Cell and Gene Therapy CDMO Market, By Application
      • 7.8.2.3 China Cell and Gene Therapy CDMO Market, By Indication
    • 7.8.3 Japan Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.3.1 Japan Cell and Gene Therapy CDMO Market, By Type
      • 7.8.3.2 Japan Cell and Gene Therapy CDMO Market, By Application
      • 7.8.3.3 Japan Cell and Gene Therapy CDMO Market, By Indication
    • 7.8.4 South Korea Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.4.1 South Korea Cell and Gene Therapy CDMO Market, By Type
      • 7.8.4.2 South Korea Cell and Gene Therapy CDMO Market, By Application
      • 7.8.4.3 South Korea Cell and Gene Therapy CDMO Market, By Indication
    • 7.8.5 India Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.5.1 India Cell and Gene Therapy CDMO Market, By Type
      • 7.8.5.2 India Cell and Gene Therapy CDMO Market, By Application
      • 7.8.5.3 India Cell and Gene Therapy CDMO Market, By Indication
    • 7.8.6 Rest of Asia Pacific Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.7.1 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Type
      • 7.8.7.2 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Application
      • 7.8.7.3 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Indication

8. Middle East & Africa Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 8.1 Middle East & Africa Cell and Gene Therapy CDMO Market: Snapshot
  • 8.2 Middle East & Africa Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
  • 8.3 Middle East & Africa Cell and Gene Therapy CDMO Market: Key Factors
  • 8.4 Middle East & Africa Cell and Gene Therapy CDMO Market: Segment Analysis
  • 8.5 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 8.5.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Type Overview
    • 8.5.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.5.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.5.4 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.6 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 8.6.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Application Overview
    • 8.6.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.6.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.7 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 8.7.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Indication Overview
    • 8.7.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.7.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.7.4 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.7.5 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact Assessment of Market Dynamics on Global Cell and Gene Therapy CDMO Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Value Chain Analysis
  • 10.2 Porter's Five Forces Model

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Competitive Positioning of Oxford Biomedica's Viral Vector Offering
  • 11.3 Market Position Matrix
  • 11.4 Market Share Analysis of Cell and Gene Therapy CDMO Market
  • 11.5 Company Profiles
    • 11.5.1 Oxford Biomedica
    • 11.5.2 Lonza Group AG
    • 11.5.3 Catalent, Inc.
    • 11.5.4 Samsung Biologics
    • 11.5.5 WuXi Biologics
    • 11.5.6 Pfizer CentreOne
    • 11.5.7 Danaher Corporation
    • 11.5.8 Thermo Fisher Scientific Inc.
    • 11.5.9 Charles River Laboratories International, Inc.
    • 11.5.10 Novartis AG

List of Figures

List of Figures

  • Figure 1: Cell & Gene Therapy Assets in Global Development
  • Figure 2: Genetically Modified Cell Therapy Breakdown
  • Figure 3: CAR-T Breakdown
  • Figure 4: Global Cell and Gene Therapy CDMO Market Size, By Value, 2019-2022 (USD Million)
  • Figure 5: Global Cell and Gene Therapy CDMO Market Size, By Value, 2023-2029 (USD Million)
  • Figure 6: Global Cell and Gene Therapy CDMO Market CAGR (%), By Value, 2019-2022, 2024-2029
  • Figure 7: Global Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 8: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Cell Therapy, 2019-2029 (USD Million)
  • Figure 9: Global Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 10: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Gene Therapy, 2019-2029 (USD Million)
  • Figure 11: Global Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 12: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Gene-modified Cell Therapies, 2019-2029 (USD Million)
  • Figure 13: Global Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 14: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Clinical, 2019-2029 (USD Million)
  • Figure 15: Global Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 16: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Pre-clinical, 2019-2029 (USD Million)
  • Figure 17: Global Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 18: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Oncology Diseases, 2019-2029 (USD Million)
  • Figure 19: Global Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 20: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Infectious Diseases, 2019-2029 (USD Million)
  • Figure 21: Global Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 22: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Neurological Disorder, 2019-2029 (USD Million)
  • Figure 23: Global Cell and Gene Therapy CDMO Market Size, Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 24: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Other Indications, 2019-2029 (USD Million)
  • Figure 25: Americas Cell and Gene Therapy CDMO Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 26: Americas Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 27: Americas Cell and Gene Therapy CDMO Market, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 28: Americas Cell and Gene Therapy CDMO Market, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 29: Americas Cell and Gene Therapy CDMO Market, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 30: Americas Cell and Gene Therapy CDMO Market, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 31: Americas Cell and Gene Therapy CDMO Market, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 32: Americas Cell and Gene Therapy CDMO Market, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 33: Americas Cell and Gene Therapy CDMO Market, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 34: Americas Cell and Gene Therapy CDMO Market, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 35: Americas Cell and Gene Therapy CDMO Market, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 36: United States Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 37: United States Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 38: United States Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 39: United States Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 40: United States Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 41: Canada Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 42: Canada Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 43: Canada Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 44: Canada Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 45: Canada Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 46: Rest of Americas Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 47: Rest of Americas Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 48: Rest of Americas Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 49: Rest of Americas Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 50: Rest of Americas Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 51: Europe Cell and Gene Therapy CDMO Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 52: Europe Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 53: Europe Cell and Gene Therapy CDMO Market, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 54: Europe Cell and Gene Therapy CDMO Market, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 55: Europe Cell and Gene Therapy CDMO Market, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 56: Europe Cell and Gene Therapy CDMO Market, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 57: Europe Cell and Gene Therapy CDMO Market, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 58: Europe Cell and Gene Therapy CDMO Market, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 59: Europe Cell and Gene Therapy CDMO Market, Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 60: Europe Cell and Gene Therapy CDMO Market, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 61: Europe Cell and Gene Therapy CDMO Market, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 62: United Kingdom Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 63: United Kingdom Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 64: United Kingdom Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 65: United Kingdom Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 66: United Kingdom Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 67: Germany Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 68: Germany Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 69: Germany Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 70: Germany Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 71: Germany Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 72: France Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 73: France Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 74: France Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 75: France Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 76: France Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 77: Italy Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 78: Italy Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 79: Italy Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 80: Italy Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 81: Italy Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 82: Rest of Europe Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 83: Rest of Europe Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 84: Rest of Europe Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 85: Rest of Europe Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 86: Rest of Europe Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 87: Asia Pacific Cell and Gene Therapy CDMO Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 88: Asia Pacific Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 89: Asia Pacific Cell and Gene Therapy CDMO Market, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 90: Asia Pacific Cell and Gene Therapy CDMO Market, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 91: Asia Pacific Cell and Gene Therapy CDMO Market, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 92: Asia Pacific Cell and Gene Therapy CDMO Market, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 93: Asia Pacific Cell and Gene Therapy CDMO Market, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 94: Asia Pacific Cell and Gene Therapy CDMO Market, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 95: Asia Pacific Cell and Gene Therapy CDMO Market, Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 96: Asia Pacific Cell and Gene Therapy CDMO Market, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 97: Asia Pacific Cell and Gene Therapy CDMO Market, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 98: China Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 99: China Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 100: China Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 101: China Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 102: China Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 103: Japan Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 104: Japan Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 105: Japan Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 106: Japan Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 107: Japan Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 108: South Korea Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 109: South Korea Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 110: South Korea Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 111: South Korea Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 112: South Korea Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 113: India Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 114: India Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 115: India Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 116: India Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 117: India Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 118: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 119: Rest of Asia Pacific Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 120: Rest of Asia Pacific Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 121: Rest of Asia Pacific Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 122: Rest of Americas Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 123: Middle east & Africa Cell and Gene Therapy CDMO Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 124: Middle east & Africa Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 125: Middle east & Africa Cell and Gene Therapy CDMO Market, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 126: Middle east & Africa Cell and Gene Therapy CDMO Market, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 127: Middle East & Africa Cell and Gene Therapy CDMO Market, By Gene-modified Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 128: Middle east & Africa Cell and Gene Therapy CDMO Market, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 129: Middle East & Africa Cell and Gene Therapy CDMO Market, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 130: Middle east & Africa Cell and Gene Therapy CDMO Market, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 131: Middle east & Africa Cell and Gene Therapy CDMO Market, Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 132: Middle east & Africa Cell and Gene Therapy CDMO Market, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 133: Middle East & Africa Cell and Gene Therapy CDMO Market, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 134: Global Impact of Drivers and Restraints
  • Figure 135: Market Share of Prominent Companies of Cell and Gene Therapy CDMO Market, 2022 (%)
  • Figure 136: Oxford Biomedica Revenues, 2020-2022 (USD Million)
  • Figure 137: Oxford Biomedica, Revenue By Business Segment, 2022 (%)
  • Figure 138: Oxford Biomedica, Revenue By Geographic Segment, 2022 (%)
  • Figure 139: Oxford Biomedica, Largest Shareholders, 2022 (%)
  • Figure 140: Lonza Group AG Revenues, 2020-2022 (USD Million)
  • Figure 141: Lonza Group AG Revenue By Customer Group, 2022 (%)
  • Figure 142: Lonza Group AG, By Infrastructure, 2022
  • Figure 143: Lonza Group AG, CDMO Sales By Customer Location , 2022 (%)
  • Figure 144: Lonza Group AG, CDMO Sales By Customer Type , 2022 (%)
  • Figure 145: Lonza Group AG, Distribution of CDMO Customers By Sales, 2022 (%)
  • Figure 146: Catalent, Inc. Revenues, 2020-2022 (USD Million)
  • Figure 147: Catalent, Inc. Revenue By Business Segment, 2022 (%)
  • Figure 148: Catalent, Inc. Revenue By Geographic Segment, 2022 (%)
  • Figure 149: Samsung Biologics Revenues, 2020-2022 (USD Million)
  • Figure 150: Samsung Biologics Revenue By Business Segment, 2022 (%)
  • Figure 151: Samsung Biologics Revenue By Geographic Segment, 2022 (%)
  • Figure 152: WuXi Biologics Revenues, 2020-2022 (USD Million)
  • Figure 153: WuXi Biologics Revenue By Business Segment, 2022 (%)
  • Figure 154: WuXi Biologics Revenue By Geographic Segment, 2022 (%)
  • Figure 155: Pfizer CentreOne Revenues, 2020-2022 (USD Million)
  • Figure 156: Pfizer CentreOne Revenue By Geographic Segment, 2022 (%)
  • Figure 157: Danaher Corporation Revenues, 2020-2022 (USD Million)
  • Figure 158: Danaher Corporation Revenue, By Business Segments, 2022 (%)
  • Figure 159: Danaher Corporation Revenue, By Geographic Segments, 2022 (%)
  • Figure 160: Thermo Fisher Scientific Inc. Revenues, 2020-2022 (USD Million)
  • Figure 161: Thermo Fisher Scientific Inc. Revenue By Business Segment, 2022 (%)
  • Figure 162: Thermo Fisher Scientific Inc. Revenue By Geographic Segment, 2022 (%)
  • Figure 163: Charles River Laboratories International, Inc. Revenues, 2020-2022 (USD Million)
  • Figure 164: Charles River Laboratories International, Inc. Revenue By Business Segment, 2022 (%)
  • Figure 165: Charles River Laboratories International, Inc. Revenue By Geographic Segment, 2022 (%)
  • Figure 166: Novartis AG Revenues, 2020-2022 (USD Million)
  • Figure 167: Novartis AG Revenue By Business Segment, 2022 (%)
  • Figure 168: Novartis AG Revenue By Geographic Segment, 2022 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: OXB's Internal Cell and Gene Therapy Pipeline

Table A3: Clinical AAV Gene Therapies for Genetic Neurological Disorders

Table A4: FDA NME Approvals, 2019-2022

Table A5: Drugs by Therapy Area

Table A6: Approved Gene, Cell, and RNA Therapies Globally, for Clinical Use

Table A7: Pipeline Therapies by Category

Table A8: Approved Gene, Cell, and RNA Therapies Globally, for Clinical Use

Table A9: Number of Therapies from Pre-clinical through Pre-registration

Table A10: Therapies in the Clinic (excludes preclinical development)

Table A11: Cell and Gene Therapy Landscape, by Region

Table A12: Landscape of Key Cell and Gene Therapy Service Providers

Table A13: United States Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A14: United States Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A15: United States Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A16: United States Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A17: United States Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A18: United States Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A19: Canada Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A20: Canada Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A21: Canada Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A22: Canada Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A23: Canada Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A24: Canada Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A25: Rest of Americas Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A26: Rest of Americas Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A27: Rest of Americas Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A28: Rest of Americas Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A29: Rest of Americas Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A30: Rest of Americas Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A31: United Kingdom Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A32: United Kingdom Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A33: United Kingdom Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A34: United Kingdom Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A35: United Kingdom Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A36: United Kingdom Elevated Work Platform (MEWP) Market, By Indication, By Value, 2023-2029 (USD Million)

Table A37: Germany Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A38: Germany Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A39: Germany Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A40: Germany Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A41: Germany Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A42: Germany Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A43: France Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A44: France Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A45: France Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A46: France Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A47: France Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A48: France Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A49: Italy Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A50: Italy Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A51: Italy Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A52: Italy Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A53: Italy Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A54: Italy Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A55: Rest of Europe Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A56: Rest of Europe Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A57: Rest of Europe Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A58: Rest of Europe Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A59: Rest of Europe Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A60: Rest of Europe Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A61: China Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A62: China Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A63: China Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A64: China Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A65: China Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A66: China Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A67: Japan Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A68: Japan Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A69: Japan Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A70: Japan Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A71: Japan Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A72: Japan Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A73: South Korea Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A74: South Korea Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A75: South Korea Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A76: South Korea Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A77: South Korea Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A78: South Korea Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A79: India Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A80: India Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A81: India Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A82: India Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A83: India Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A84: India Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A85: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A86: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A87: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A88: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A89: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A90: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A91: Oxford Biomedica Financials, 2020-2022

Table A92: Lonza Group AG Financials, 2020-2022

Table A93: Catalent, Inc. Financials, 2020-2022

Table A94: Samsung Biologics Financials, 2020-2022

Table A95: WuXi Biologics Financials, 2020-2022

Table A96: Pfizer CentreOne Financials, 2020-2022

Table A97: Danaher Corporation Financials, 2020-2022

Table A98: Thermo Fisher Scientific Inc. Financials, 2020-2022

Table A99: Charles River Laboratories International, Inc. Financials, 2020-2022

Table A100: Novartis AG Financials, 2020-2022